|Population source||Exposure definition||Non-exposure definition||Sample size||Rmk|
|Pregnancy outcomes from adults with relapsing MS who received at least one dose of daclizumab in the phase II SELECT study, phase III DECIDE study , and ongoing phase III immunogenicity OBSERVE study, or their respective extension studies.||MS women who became pregnant while receiving daclizumab or <=6 months after the final dose||
MS women who have stopped daclizumab at least 6 months before becoming pregnant.
|38 / 6||Half-life: 21 days (7*21 days = 147 days : about 5 months). In the event of pregnancy, daclizumab was discontinued and safety monitoring continued.|